Kyndryl's Financial Reporting Failures Lead to Class Action Lawsuit
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy KD?
Source: Globenewswire
- Financial Control Failures: Kyndryl's amended reports filed on February 17, 2026, reveal ineffective internal controls over financial reporting as of September 30, 2025, leading to a 55% stock price drop on February 9, 2026, and a market cap loss exceeding $2.4 billion, severely undermining investor confidence.
- Executive Departures Impact: The abrupt resignations of CFO David Wyshner and General Counsel Edward Sebold on February 5, 2026, have heightened concerns regarding corporate governance and financial transparency, potentially prompting further investor withdrawals.
- SEC Investigation Intensifies: Kyndryl disclosed that the SEC is investigating its cash management practices, indicating significant issues with financial transparency and compliance, which could result in stricter regulatory repercussions for the company.
- Class Action Lawsuit Initiated: A securities class action lawsuit has been triggered by the February 9 disclosure, representing investors who purchased Kyndryl securities between August 7, 2024, and February 9, 2026, potentially leading to substantial financial liabilities for the company and further impacting its financial stability.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KD
Wall Street analysts forecast KD stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 12.310
Low
28.00
Averages
33.25
High
40.00
Current: 12.310
Low
28.00
Averages
33.25
High
40.00
About KD
Kyndryl Holdings, Inc. is a provider of mission-critical enterprise technology services offering advisory, implementation and managed service capabilities to customers in more than 60 countries. The Company designs, builds, manages and modernizes complex information systems around the world. Its segments include United States, Japan, Principal Markets and Strategic Markets. It offers services across domains, such as cloud services, core enterprise and zCloud services, applications, data and artificial intelligence (AI) services, digital workplace services, security and resiliency services and network and edge services. Its advisory and implementation services are branded as Kyndryl Consult. It provides end-to-end enterprise data services, including data transformation, data architecture and management, data governance and compliance and data migration. It provides comprehensive enterprise cybersecurity services for chief information security officers (CISOs) and chief risk officers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Kyndryl's Financial Reporting Failures Lead to Class Action Lawsuit
- Financial Control Failures: Kyndryl's amended reports filed on February 17, 2026, reveal ineffective internal controls over financial reporting as of September 30, 2025, leading to a 55% stock price drop on February 9, 2026, and a market cap loss exceeding $2.4 billion, severely undermining investor confidence.
- Executive Departures Impact: The abrupt resignations of CFO David Wyshner and General Counsel Edward Sebold on February 5, 2026, have heightened concerns regarding corporate governance and financial transparency, potentially prompting further investor withdrawals.
- SEC Investigation Intensifies: Kyndryl disclosed that the SEC is investigating its cash management practices, indicating significant issues with financial transparency and compliance, which could result in stricter regulatory repercussions for the company.
- Class Action Lawsuit Initiated: A securities class action lawsuit has been triggered by the February 9 disclosure, representing investors who purchased Kyndryl securities between August 7, 2024, and February 9, 2026, potentially leading to substantial financial liabilities for the company and further impacting its financial stability.
See More
Faruqi & Faruqi Encourages Kyndryl Investors to Reach Out
- Legal Investigation: Faruqi & Faruqi LLP is investigating potential claims against Kyndryl Holdings, Inc., particularly urging investors who purchased securities between August 7, 2024, and February 9, 2026, to contact them before the April 13, 2026 deadline to seek lead plaintiff status.
- False Statement Allegations: The lawsuit alleges that Kyndryl and its executives violated federal securities laws by failing to disclose deficiencies in manufacturing Inovio's CELLECTRA device, misleading investors about the regulatory and commercial prospects of the device.
- Stock Price Decline Impact: Following the FDA's acceptance of Inovio's Biologics License Application without adequate justification for accelerated approval, Kyndryl's stock price fell by 24.45% to close at $1.73 per share on December 29, 2025, reflecting market concerns about the company's future.
- Investor Rights Protection: Faruqi & Faruqi encourages anyone with information regarding Kyndryl's conduct, including whistleblowers and former employees, to contact the firm to assist in potential class action litigation, ensuring investor rights are safeguarded.
See More
Kyndryl and uniQure Shareholder Lawsuit Reminder
- Kyndryl Lawsuit Overview: A shareholder class action lawsuit against Kyndryl Holdings, Inc. alleges that the company made materially false and misleading statements regarding its financial statements issued between August 7, 2024, and February 9, 2026, encouraging affected investors to contact legal counsel to discuss their rights if they suffered significant losses during this period.
- uniQure Lawsuit Details: The class action lawsuit against uniQure N.V. claims that the company failed to disclose material facts regarding the design of its pivotal study between September 24, 2025, and October 31, 2025, with a deadline of April 13, 2026, for investors to apply to be appointed lead plaintiff to protect their interests.
- Law Firm Background: Holzer & Holzer, LLC, recognized as an ISS top-rated securities litigation law firm for 2021, 2022, 2023, and 2025, has been dedicated to vigorously representing shareholders and investors since its founding in 2000, successfully recovering hundreds of millions of dollars for victims of corporate misconduct.
- Contact Information: Investors seeking more information or legal assistance can reach Corey D. Holzer, Esq. at (888) 508-6832 or via email at cholzer@holzerlaw.com, or visit the firm's website for additional resources.
See More
Multiple Companies Face Class Action Lawsuits
- Oracle Lawsuit: Oracle Corporation faces a class action lawsuit for the period from June 12 to December 16, 2025, with allegations of misleading statements leading to investor losses exceeding $50,000, as its AI infrastructure strategy is expected to significantly increase capital expenditures without corresponding revenue growth, potentially jeopardizing its debt and credit rating.
- Paysafe Risks: Paysafe Limited is under scrutiny in a class action lawsuit covering March 4 to November 12, 2025, for failing to disclose significant exposure to a single high-risk client, which has led to understated credit loss reserves and could negatively impact revenue growth, making it unlikely to meet its 2025 financial guidance.
- Inovio Manufacturing Deficiencies: Inovio Pharmaceuticals is involved in a class action lawsuit for the period from October 10, 2023, to December 26, 2025, due to deficiencies in manufacturing its CELLECTRA device, which may hinder its ability to submit a BLA to the FDA on time, overstating its regulatory and commercial prospects.
- Kyndryl Financial Misstatements: Kyndryl Holdings faces a class action lawsuit for the period from August 7, 2024, to February 9, 2026, alleging material misstatements in financial reports and inadequate internal controls, which could prevent timely filing of its quarterly report, further damaging investor confidence.
See More
Kyndryl Faces Class Action Lawsuit Amid Internal Control Issues
- Stock Price Plunge: Kyndryl's shares fell by 55% on February 9, 2026, after the company announced it would not timely file its quarterly report, resulting in a loss of over $3 billion in market capitalization, reflecting severe market reaction to internal control issues.
- Internal Control Deficiencies: The company disclosed significant weaknesses in its internal controls, including issues related to 'tone at the top' and executive departures, raising investor concerns about financial transparency and potential future compliance risks.
- Legal Action Initiated: Hagens Berman has filed a class action lawsuit against Kyndryl, alleging false and misleading statements in financial reporting, which could adversely affect investor rights and confidence in the company.
- SEC Document Requests: Kyndryl revealed it received document requests from the SEC regarding matters under review by its Audit Committee, which may lead to deeper regulatory scrutiny and potential legal consequences.
See More
Kyndryl Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Kyndryl Holdings, Inc. for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between August 7, 2024, and February 9, 2026, with a deadline to contact the firm by April 13, 2026.
- Misleading Financial Statements: The complaint alleges that Kyndryl materially misstated its financial statements and failed to maintain adequate internal controls, rendering its public statements false and misleading throughout the class period, which has significant implications for investor trust and regulatory scrutiny.
- Investor Damages: As the market learned the truth about Kyndryl's financial mismanagement, investors suffered losses, prompting the Schall Law Firm to encourage affected shareholders to join the lawsuit to recover damages, highlighting the company's lack of transparency and compliance.
- Legal Consultation Offer: The Schall Law Firm offers free legal consultations to affected shareholders, urging them to discuss their rights, which underscores the firm's specialization in securities class action lawsuits and its commitment to protecting investor rights.
See More
Kyndryl's Financial Reporting Failures Lead to Class Action Lawsuit
- Financial Control Failures: Kyndryl's amended reports filed on February 17, 2026, reveal ineffective internal controls over financial reporting as of September 30, 2025, leading to a 55% stock price drop on February 9, 2026, and a market cap loss exceeding $2.4 billion, severely undermining investor confidence.
- Executive Departures Impact: The abrupt resignations of CFO David Wyshner and General Counsel Edward Sebold on February 5, 2026, have heightened concerns regarding corporate governance and financial transparency, potentially prompting further investor withdrawals.
- SEC Investigation Intensifies: Kyndryl disclosed that the SEC is investigating its cash management practices, indicating significant issues with financial transparency and compliance, which could result in stricter regulatory repercussions for the company.
- Class Action Lawsuit Initiated: A securities class action lawsuit has been triggered by the February 9 disclosure, representing investors who purchased Kyndryl securities between August 7, 2024, and February 9, 2026, potentially leading to substantial financial liabilities for the company and further impacting its financial stability.
See More
Faruqi & Faruqi Encourages Kyndryl Investors to Reach Out
- Legal Investigation: Faruqi & Faruqi LLP is investigating potential claims against Kyndryl Holdings, Inc., particularly urging investors who purchased securities between August 7, 2024, and February 9, 2026, to contact them before the April 13, 2026 deadline to seek lead plaintiff status.
- False Statement Allegations: The lawsuit alleges that Kyndryl and its executives violated federal securities laws by failing to disclose deficiencies in manufacturing Inovio's CELLECTRA device, misleading investors about the regulatory and commercial prospects of the device.
- Stock Price Decline Impact: Following the FDA's acceptance of Inovio's Biologics License Application without adequate justification for accelerated approval, Kyndryl's stock price fell by 24.45% to close at $1.73 per share on December 29, 2025, reflecting market concerns about the company's future.
- Investor Rights Protection: Faruqi & Faruqi encourages anyone with information regarding Kyndryl's conduct, including whistleblowers and former employees, to contact the firm to assist in potential class action litigation, ensuring investor rights are safeguarded.
See More
Kyndryl and uniQure Shareholder Lawsuit Reminder
- Kyndryl Lawsuit Overview: A shareholder class action lawsuit against Kyndryl Holdings, Inc. alleges that the company made materially false and misleading statements regarding its financial statements issued between August 7, 2024, and February 9, 2026, encouraging affected investors to contact legal counsel to discuss their rights if they suffered significant losses during this period.
- uniQure Lawsuit Details: The class action lawsuit against uniQure N.V. claims that the company failed to disclose material facts regarding the design of its pivotal study between September 24, 2025, and October 31, 2025, with a deadline of April 13, 2026, for investors to apply to be appointed lead plaintiff to protect their interests.
- Law Firm Background: Holzer & Holzer, LLC, recognized as an ISS top-rated securities litigation law firm for 2021, 2022, 2023, and 2025, has been dedicated to vigorously representing shareholders and investors since its founding in 2000, successfully recovering hundreds of millions of dollars for victims of corporate misconduct.
- Contact Information: Investors seeking more information or legal assistance can reach Corey D. Holzer, Esq. at (888) 508-6832 or via email at cholzer@holzerlaw.com, or visit the firm's website for additional resources.
See More
Multiple Companies Face Class Action Lawsuits
- Oracle Lawsuit: Oracle Corporation faces a class action lawsuit for the period from June 12 to December 16, 2025, with allegations of misleading statements leading to investor losses exceeding $50,000, as its AI infrastructure strategy is expected to significantly increase capital expenditures without corresponding revenue growth, potentially jeopardizing its debt and credit rating.
- Paysafe Risks: Paysafe Limited is under scrutiny in a class action lawsuit covering March 4 to November 12, 2025, for failing to disclose significant exposure to a single high-risk client, which has led to understated credit loss reserves and could negatively impact revenue growth, making it unlikely to meet its 2025 financial guidance.
- Inovio Manufacturing Deficiencies: Inovio Pharmaceuticals is involved in a class action lawsuit for the period from October 10, 2023, to December 26, 2025, due to deficiencies in manufacturing its CELLECTRA device, which may hinder its ability to submit a BLA to the FDA on time, overstating its regulatory and commercial prospects.
- Kyndryl Financial Misstatements: Kyndryl Holdings faces a class action lawsuit for the period from August 7, 2024, to February 9, 2026, alleging material misstatements in financial reports and inadequate internal controls, which could prevent timely filing of its quarterly report, further damaging investor confidence.
See More
Kyndryl Faces Class Action Lawsuit Amid Internal Control Issues
- Stock Price Plunge: Kyndryl's shares fell by 55% on February 9, 2026, after the company announced it would not timely file its quarterly report, resulting in a loss of over $3 billion in market capitalization, reflecting severe market reaction to internal control issues.
- Internal Control Deficiencies: The company disclosed significant weaknesses in its internal controls, including issues related to 'tone at the top' and executive departures, raising investor concerns about financial transparency and potential future compliance risks.
- Legal Action Initiated: Hagens Berman has filed a class action lawsuit against Kyndryl, alleging false and misleading statements in financial reporting, which could adversely affect investor rights and confidence in the company.
- SEC Document Requests: Kyndryl revealed it received document requests from the SEC regarding matters under review by its Audit Committee, which may lead to deeper regulatory scrutiny and potential legal consequences.
See More
Kyndryl Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Kyndryl Holdings, Inc. for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between August 7, 2024, and February 9, 2026, with a deadline to contact the firm by April 13, 2026.
- Misleading Financial Statements: The complaint alleges that Kyndryl materially misstated its financial statements and failed to maintain adequate internal controls, rendering its public statements false and misleading throughout the class period, which has significant implications for investor trust and regulatory scrutiny.
- Investor Damages: As the market learned the truth about Kyndryl's financial mismanagement, investors suffered losses, prompting the Schall Law Firm to encourage affected shareholders to join the lawsuit to recover damages, highlighting the company's lack of transparency and compliance.
- Legal Consultation Offer: The Schall Law Firm offers free legal consultations to affected shareholders, urging them to discuss their rights, which underscores the firm's specialization in securities class action lawsuits and its commitment to protecting investor rights.
See More
